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This study compared ﬁeld-in-ﬁeld (FIF) radiotherapy with conformal radiotherapy with physical 
wedges for the treatment of unilateral cervical malignant lymphoma.  Two treatment plans,  the FIF 
technique and conformal RT,  were generated for each of 32 patients with unilateral cervical malig-
nant lymphoma.  To compare the 2 treatment plans,  dose-volume histograms of the planning target 
volume (PTV),  the thyroid,  submandibular gland,  carotid artery,  mucosa,  spinal cord,  and sur-
rounding normal tissue,  and monitor unit (MU) were analyzed.  The FIF technique showed signiﬁcant 
reduction in the mean dose of thyroid,  submandibular gland,  carotid artery and mucosa,  the maxi-
mum dose of the spinal cord and PTV,  and the volume receiving＞107ｵ of the prescribed dose of 
surrounding normal tissue (p＜0.001).  In addition,  there were gains in the homogeneity index of the 
PTV for FIF.  Furthermore,  the total MU was also lower for the FIF technique than for the wedge 
technique (p＜0.001).  Compared with the wedge technique,  the FIF technique improved the dose homo-
geneity of the PTV,  reduced the dose to normal structures,  and was associated with fewer MUs in the 
treatment of patients with cervical malignant lymphoma.
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adiotherapy remains a key component of com-
bined modality therapy for patients with malig-
nant lymphoma [1].  In regard to the optimal treat-
ment volume for radiotherapy (RT) of localized 
malignant lymphoma,  involved-ﬁeld RT (IFRT) is usual 
[1-5].  The frequency of cervical lymph node involve-
ment is high in cases of primary lesions of Hodgkinʼs 
lymphoma and non-Hodgkinʼs lymphoma (NHL) [6-10].
　 Engert et al.  reported that,  among lymphoma 
patients treated with high-dose radiation,  the rates of 
radiation toxicity were higher in patients with early-
stage Hodgkinʼs lymphoma.  The most common acute 
toxicities were dysphagia and mucositis [5].
　 To limit the adverse events of RT,  the treatment 
aim has been to focus the prescribed dose on the tar-
get as much as possible and to avoid exposure to the 
surrounding organs and normal tissues.  By reducing 
the volume of normal tissues exposed to intermediate- 
to high-dose irradiation,  intensity-modulated radiation 
therapy (IMRT) has the potential to substantially 
improve dose distribution.  However,  IMRT is rarely 
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employed for the treatment of patients with malignant 
lymphoma [8],  and the parallel-opposed pair tech-
nique is generally used in cervical radiation therapy.
　 The ﬁeld-in-ﬁeld (FIF) technique is generally 
regarded as a manual,  forward intensity-modulated 
therapy.  Prabhakar et al.  [11] reported some advan-
tages of using the FIF technique over the wedge 
technique,  which uses a physical,  wedge-shaped ﬁlter 
to provide gradation of radiation beams.  First,  the 
FIF technique reduces dose scattering in the patient.  
Second,  the total monitor unit (MU) usage is consid-
erably reduced.  Third,  the total time required for 
treating a patient can be reduced.  Fourth,  some hot 
spots may persist even after the use of the wedge 
technique because of extreme tissue homogeneity and 
counter irregularities; these can be avoided with the 
FIF technique.  In general,  the higher number of MUs 
with the wedge technique,  associated with increased 
dose scattering,  can,  along with leaf radiation leak-
age,  increase the risk of secondary cancers [12,  13].
　 Many studies have compared ﬁeld-in-ﬁeld (FIF) RT 
with conformal RT using the wedge technique in 
breast cancer [14-16],  but,  to the best of our knowl-
edge,  a study comparing the eﬀectiveness of these 
modalities in unilateral cervical lymphoma has not yet 
been reported.
　 The wedge technique,  which is associated with a 
longer treatment time,  is not typically used in RT for 
bilateral cervical lymphoma.  However,  the wedge 
technique can be used in RT for unilateral cervical 
lymphoma.  We therefore considered that the advan-
tages of RT using the FIF technique may be more 
pronounced for unilateral cervical lymphoma than for 
bilateral cervical lymphoma.  Thus,  we limited our 
study to patients with unilateral cervical lymphoma 
only.
　 The current study was conducted to evaluate the 
clinical beneﬁt of the FIF technique compared with 
conformal RT using the physical wedge technique for 
the treatment of unilateral cervical lymphoma.
Patients and Methods
　 Between April 2002 and August 2012,  40 patients 
with cervical malignant lymphoma underwent RT at 
Okayama University Hospital.  Of the 40 patients,  32 
patients met the following criteria and were thus eli-
gible for this study: (1) Pre-chemotherapy CT images 
were available; (2) There were no extranodal lesions;  
and (3) The cervical lymphoma was unilateral.
　 Patient characteristics are shown in Table 1.  This 
study complied with the Declaration of Helsinki 1989 
recommendations and was approved by the ethics com-
mittee of the Okayama University.
　 All patients were scanned in the supine position 
with their arms at their sides using immobilization 
devices usually consisting of thermoplastic masks.  
Data from planning computed tomography (CT) scans 
taken at 2- or 5-mm intervals were transferred to the 
radiation treatment planning system (XiO 4.62;  
Computerized Medical System,  Inc.,  St Louis,  MO,  
USA).  Two treatment plans against unilateral cervical 
malignant lymphoma were generated for the study for 
each patient: for the FIF technique and for conformal 
RT.  A total dose of 30 Gy in 15 daily fractions of 2 
Gy was planned.
　 Treatment was simulated using 4 MV X-rays with 
a dose rate of 400MU/min,  using an ONCOR 
Impression Plus linear accelerator (Siemens Medical 
Systems,  Erlangen,  Germany) equipped with 80 pairs 
of double-focused multi-leaf collimators (MLCs) with 
a leaf slice thickness of 5mm.  At least 2 open beams 
consisting of 2 anterior-posterior (AP) parallel-opposed 
ﬁelds (gantry angles,  0°-180°) shaped with MLCs on 
a beamʼs-eye-view (BEV) were used.
　 The weight point was set so that the dose gradient 
was low,  and the planning target volume (PTV) of 
V95 was similar for both plans.  The target ﬁeld was 
designated according to the guidelines of the Cancer 
and Leukemia Group B study for Hodgkinʼs lymphoma 
[17] (Table 2).  The isocenter was placed at the same 
point for both plans.  The clinical target volume (CTV) 
included ipsilateral neck node levels I-VI,  the parotid 
area,  and the volume of pre-chemotherapy involved 
lymph nodes plus a 5-mm margin based on anatomical 
bases reviewed by Lengelé B et al.  [18].  The PTV 
included the CTV plus a 3-mm margin.  Target vol-
umes and organs at risk were delineated by the same 
radiologist (M.Y.) and checked by a senior radiologist 
(N. K. ).
　 For conformal RT,  the MLCs in the AP and pos-
terior-anterior (PA) ﬁelds were shaped to the noted 
ﬁeld in the BEV and the collimator was set to 0° or 
180°.  A conventional hard wedge was applied at 15°.
　 For the FIF technique,  a step-by-step iterative 
process inherent to forward planning was used.  The 
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starting point was the conventional AP-PA plan with 
subsequent manual addition of 2 or 4 MLC-shaped 
subﬁelds with the same AP-PA isocenter and gantry 
position.  Optimization was obtained by weighting the 
open pairs and avoiding hot spots (＞107ｵ of the dose 
prescription).  Only segments with more than 5 MUs 
were used.  An example of one of the FIF technique 
portals that consists of one main AP ﬁeld (Fig.  1A) 
and 2 subﬁelds (Fig.  1B and C) is depicted in Fig.  1.
　 Plan evaluation. To evaluate and compare 
treatment plans,  dose-volume histograms (DVHs) were 
assessed quantitatively for each plan and patient.  
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Table 1　 Patient　characteristics
Age Gender Lesion Level Histologic type Lesion volume (cc)
1 71 F IV Follicular 7.03
2 48 M IIA Diﬀuse large B cell 9.91
3 30 F VB Diﬀuse large B cell 2.68
4 59 M IIA Diﬀuse large B cell 2.68
5 55 M IIA Diﬀuse large B cell 3.77
6 60 M IIA Diﬀuse large B cell 2.65
7 64 F IB Diﬀuse large B cell 5.40
8 80 F IIB Diﬀuse large B cell 0.79
9 57 F IIA,  IIB Diﬀuse large B cell 9.70
10 60 M IB Diﬀuse large B cell 4.39
11 58 M IB Follicular 2.47
12 62 M III,  IV Diﬀuse large B cell 14.92
13 57 M IIA,  III Follicular 3.53
14 73 F IB MALT 3.65
15 45 F IV Diﬀuse large B cell 3.03
16 60 F IIB,  III,  IV Diﬀuse large B cell 41.82
17 73 M IIB,  III,  IV B-cell lymphoblastic 11.80
18 73 M IB,  IIA Diﬀuse large B cell 4.79
19 51 M IIA,  III Follicular 18.20
20 69 M IIA Follicular 2.71
21 57 M IIA Diﬀuse large B cell 1.83
22 46 F IIA,  III Follicular 11.59
23 49 M IIA Diﬀuse large B cell 0.78
24 82 M IIA,  IIB,  III,  IV Diﬀuse large B cell 46.45
25 15 F IV,  VB Nodular sclerosis 26.72
26 19 M IV Nodular sclerosis 3.56
27 44 M IIA Diﬀuse large B cell 6.84
28 47 M IIB Follicular 11.22
29 64 F IA,  IB,  IIA Low grade B cell 73.86
30 23 F IV Nodular sclerosis 0.97
31 27 F IV Diﬀuse large B cell 9.84
32 57 F IIA Diﬀuse large B cell 2.27
MALT,  mucosa-associated lymphoid tissue.
Table 2　 The involved ﬁeld borders of unilateral cervical/supraclavicular region in the guidelines for Cancer and Leukemia Group B 
studies in Hodgkinʼs lymphoma
Involvement at any cervical level with or without involvement of the supraclavicular (SCL) nodes
Arm position Akimbo or at sides
Upper border 2cm above the lower tip of the mastoid process and mid-point through the chin
Lower border 2cm below the bottom of the clavicle
Lateral border To include the medial 2/3 of the clavicle
Medial border At the contralateral transverse processes
DVHs were computed using the following parameters:
(i)　 The percentage of the volume of the PTV that 
receives at least 95ｵ of the prescribed dose 
(PTV V95)
(ii)　 The percentage of the volume of the PTV that 
receives＞107ｵ of the prescribed dose (PTV 
V107)
(iii)　 The maximum dose to the PTV (PTV Dmax)
(iv)　 The volume of surrounding normal tissues that 
receives＞107ｵ of the prescribed dose (sur-
rounding normal tissue V107)
(v)　 The percentage of the volume of PTV that 
receives a dose of between 95ｵ and 107ｵ of 
the prescribed dose (PTV homogeneity index 
(HI))
(vi)　 The mean doses to the thyroid (thyroid Dmean)
The mean doses to the submandibular gland 
(submandibular gland Dmean)
The mean doses to the carotid artery (carotid 
artery Dmean)
The mean doses to the mucosa (mucosa Dmean)
(vii)　 The maximum dose to the spinal cord (spinal 
cord Dmax)
　 Statistical analyses. Data processing and 
statistical analyses were carried out using SPSS 
19.0 (SPSS,  Chicago,  IL,  USA).  Analyses were 
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Fig. 1　 Example of the FIF technique portals: A,  main anterior-posterior (AP) ﬁeld; B,  subﬁeld 1; C,  subﬁeld 2.  The hot spots 
(＞107% of the dose prescription) are shown in red color.  These subﬁelds were designed to avoid the hot spots.
performed using the Wilcoxon signed rank test to 
determine whether there was a signiﬁcant diﬀerence 
in any of the parameters examined.  Diﬀerences with 
p value＜0.05 were considered statistically signiﬁ-
cant.
Results
　 Results of the analyses are presented in Table 3.  
Brieﬂy,  the PTV V95 was similar for both tech-
niques.  The Dmean of the thyroid,  submandibular 
gland,  carotid artery,  and were all signiﬁcantly lower 
with the FIF technique (p＜0.001),  as was the Dmax 
for the spinal cord (p＜0.001).
　 In addition,  the FIF technique was signiﬁcantly 
better than the wedge technique (p＜0.001) in 
decreasing PTV V107.  Finally,  there was a signiﬁ-
cant diﬀerence in the mean total MUs between the FIF 
and wedge techniques (p＜0.001) equivalents to a mean 
of 17.9 sec of machine treatment on average,  assum-
ing a dose rate of 400MU/min.
Discussion
　 Patients with malignant lymphoma are usually 
treated with a combination of chemotherapy and IFRT.  
Investigators at the MD Anderson Cancer Center 
reviewed 469 patients with diﬀuse large B-cell lym-
phoma treated between 2001 and 2007 with rituximab 
plus cyclophosphamide,  doxorubicin,  vincristine,  and 
prednisone (R-CHOP,  6-8 cycles) with or without 
radiotherapy (RT).  Of these patients,  40ｵ had stage 
I or II disease and 60ｵ had stage III or IV disease.  
Overall,  30ｵ received consolidation involved-ﬁeld 
RT (IFRT) at a dose of 30-39 Gy after a complete 
response (CR) to chemotherapy.  Local control was 
achieved in 100ｵ of patients,  with all relapses out-
side the RT ﬁeld [2,  3].  Clinical trials have demon-
strated that IFRT shows an eﬃcacy equivalent to 
those of extended-ﬁeld or subtotal-lymphoid irradiation 
in the context of combined modality therapy programs,  
and IFRT has been adopted as the standard for com-
bined modality therapy [4,  5,  19].  However,  the 
optimal treatment volume or ﬁeld size for RT of local-
ized NHL is somewhat controversial because of the 
lack of deﬁnitive phase III trials.  Many of the conclu-
sions regarding appropriate ﬁeld size are extrapolated 
from information regarding patterns of failure.  In view 
of this,  treatment of the original volume plus the 
adjacent nodal areas has largely been abandoned,  sug-
gesting that IFRT is an appropriate treatment for 
patients with NHL [4,  5,  19].  Two-thirds of NHL 
lesions are nodal at presentation and one-third are 
extranodal,  whereas in Hodgkinʼs lymphoma,  extran-
odal lesions are rare.  Hodgkinʼs lymphoma mostly 
originates in the lymph nodes,  and＞80ｵ of the 
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Table 3　 Comparison of DVH parameters and MU between the FIF technique and wedge technique
FIF Wedge P value
PTV V95 (%) 85.81±9.10 85.95±8.41 0.758
V107 (%) 1.06±2.76 10.55±11.07 ＜0.001
Dmax (Gy) 32.43±0.74 33.11±0.78 ＜0.001
HI (%) 84.87±9.37 76.50±10.76 ＜0.001
Thyroid Dmean (Gy) 28.80±1.57 30.52±4.42 ＜0.001
SG Dmean (Gy) 28.88±1.55 29.38±1.54 ＜0.001
CA Dmean (Gy) 29.26±1.77 29.68±1.80 ＜0.001
Spinal cord Dmax (Gy) 30.83±0.93 31.70±1.24 ＜0.001
Mucosa Dmean (Gy) 31.56±0.90 32.67±2.41 ＜0.001
SNT V＞V107 (ml) 3.79±6.10 41.52±55.99 ＜0.001
MU 223.91±20.45 343.56±12.73 ＜0.001
SG,  submandibular gland; CA,  carotid artery; SNT,  surrounding normal tissues; FIF,  ﬁeld-in-ﬁeld technique; Wedge,  wedge 
technique; PTV,  planning target volume. (mean ± standard deviation)
patients present with cervical lymph node involvement.  
Likewise,  in NHL,  the neck is the most frequent sites 
of nodal involvement (70ｵ of the cases),  followed by 
the groin (60ｵ),  and axilla (50ｵ) [9,  10].  Therefore 
we evaluated the FIF technique compared with con-
formal RT for the treatment of cervical lymphoma.
　 The data demonstrate the clear advantages of using 
the FIF radiotherapy technique as opposed to the 
conformal RT using wedge technique for treating 
patients with unilateral malignant cervical lymphoma.  
The Dmean for all areas was signiﬁcantly reduced and 
the PTV 107 was signiﬁcantly lower for FIF,  thereby 
minimizing patient exposure to radiation and reducing 
the likelihood of oﬀ-target radiation damage to other 
organs.  In addition,  the FIF technique signiﬁcantly 
improved PTV homogeneity and decreased the total 
MUs.  The reduction in MUs speeds up the treatment 
time and improve throughput on linac,  which is obvi-
ously advantageous for the patient.
　 In a retrospective study involving 910 patients,  
Elerding et al.  showed a trend towards an increased 
incidence of stroke after neck irradiation in patients 
with HD,  NHL,  or head and neck carcinoma [20].  In 
addition,  asymptomatic carotid arterial disease occurs 
frequently in young patients after neck radiation 
therapy for Hodgkinʼs lymphoma [21].  And,  even 
though the arterial region was diﬀerent,  Darby et al.  
reported a linear relationship between the rate of 
major coronary events and heart exposure,  with a 
7.4ｵ increase in the rate per Gy [22].  These ﬁnd-
ings suggest that the improved dose distribution with 
the FIF technique could also reduce the risk of carotid 
arterial diseases associated with RT.
　 The main disadvantage of the FIF technique is the 
long planning time however,  we recommend this tech-
nique because of the many advantages explained above.
　 Our study limitation is the diﬀerence between 
interobserver and intraobserver.  Some errors may 
have been introduced in our method of contouring.  But 
we consider that such errors would be trivial because 
we deﬁned the target volume delineation and the 
radiation techniques in detail.
　 In conclusion,  the FIF technique improved dose 
homogeneity of the PTV in the management of unilat-
eral cervical malignant lymphoma and reduced the dose 
to normal structures and the total MUs,  compared 
with the conventional wedge technique.
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